Personalized medicine for non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 10, Issue 10, 2010, Pages 1601-1611

  Mok, Tony S ^a,b   Zhou, Qing ^c   Leung, Linda ^a   Loong, Herbert H ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

epidermal growth factor; erlotinib; gefitinib; individualized medicine; non small cell lung carcinoma; receptor; receptor protein tyrosine kinases

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; SUNITINIB; VANDETANIB;

ANTIANGIOGENIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DRUG EFFICACY; FUSION GENE; GENE MUTATION; HUMAN; LOBECTOMY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MOLECULARLY TARGETED THERAPY; PHARMACOGENOMICS; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 77958102568     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.76     Document Type: Review

References (92)

1. Global Cancer Facts & Figures. American Cancer Society (2009).
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
3. Postmus PE, Brambilla E, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J. Thorac. Oncol. 2(8), 686-693 (2007). (Pubitemid 47357520)
4. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2(8), 706-714 (2007). (Pubitemid 47357522)
5. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
6. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005).
7. S.976: Genomics and Personalized Medicine Act of 2007. United States Congress, Washington DC, USA (2007).
8. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26(21), 3552-3559 (2008).
9. Burdett S, Stewart L. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 47(1), 81-83 (2005). (Pubitemid 39643244)
10. Lally BE, Zelterman D, Colasanto JM et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J. Clin. Oncol. 24(19), 2998-3006 (2006).
11. Burdett S, Pignon JP. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375(9722), 1267-1277 (2010).
12. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 17(12), 1818-1825 (2006).
13. Olaussen KA, Fouret P, Kroemer G. ERCC1-specific immunostaining in non-small-cell lung cancer. N. Engl. J. Med. 357(15), 1559-1561 (2007).
14. Gan PP, Pasquier E, Kavallaris M. Class III b-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 67(19), 9356-9363 (2007).
15. Seve P, Lai R, Ding K et al. Class III b-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin. Cancer Res. 13(3), 994-999 (2007).
16. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10(4), 1318-1325 (2004).
17. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 22(2), 330-353 (2004).
18. Dillman RO, Herndon J, Seagren SL et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J. Natl Cancer Inst. 88(17), 1210-1215 (1996).
19. Sause W, Kolesar P, Taylor SI et al. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117(2), 358-364 (2000).
20. Le Chevalier T, Arriagada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotehrapy in unresectable non-small cell lung carcinoma. Lung Cancer 10(Suppl. 1), S239-S244 (1994). (Pubitemid 24140376)
21. Curran W Jr, Scott C, Langer C et al. Long-term benefit is observed in a Phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc. Am. Soc. Clin. Oncol. 22, 621 (2003).
22. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 17(9), 2692-2699 (1999).
23. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46(1), 87-98 (2004).
24. Gandara DR, Chansky K, Albain KS et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a Phase II Southwest Oncology Group Study (S9504). Clin. Lung Cancer 8(2), 116-121 (2006).
25. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J. Clin. Oncol. 26(35), 5755-5760 (2008).
26. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol. 26(15), 2450-2456 (2008).
27. Vokes EE, Herndon JE 2nd, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J. Clin. Oncol. 25(13), 1698-1704 (2007).
28. Kim S, Kim M, Choi E et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC). Randomized Phase III trial. Proc. Am. Soc. Clin. Oncol. Part I (2007).
29. van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J. Natl Cancer Inst. 99(6), 442-450 (2007).
30. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a Phase III randomised controlled trial. Lancet 374(9687), 379-386 (2009).
31. No authors listed. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br. Med. J. 311, 899-909 (1995).
32. Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 18(3), 623-631 (2000).
33. Kelly K, Crowley J, Bunn PA Jr et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19(13), 3210-3218 (2001).
34. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20(21), 4285-4291 (2002).
35. Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J. Clin. Oncol. 21(21), 3909-3917 (2003).
36. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 21(16), 3016-3024 (2003).
37. Delbaldo C, Michiels S, Syz N et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292(4), 470-484 (2004).
38. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl Cancer Inst. 99(11), 847-857 (2007).
39. Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 27(36), 6251-6266 (2009).
40. Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004).
41. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095-2103 (2000).
42. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 372(9652), 1809-1818 (2008).
43. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
44. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
45. Travis W, Colby T, Corrin B et al. World Health Organization International Histological Classification of Tumors: Histological Typing of Lung and Pleural Tumors (3rd Edition). Springer-Verlag, Berlin Heidelberg, Germany (1999).
46. Peterson P, Park k, Fossella F et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a Phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Presented at: European Conference on Clincial Oncology (ECCO). Barcelona, Spain, 23-27 September 2007.
47. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008).
48. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase 3 study. Lancet 374(9699), 1432-1440 (2009).
49. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107(7), 1589-1596 (2006).
50. Simon G, Sharma A, Li X et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 25(19), 2741-2746 (2007).
51. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a Phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 25(19), 2747-2754 (2007).
52. Folkman J. Is angiogenesis an organizing principle in biology and medicine? J. Pediatr. Surg. 42(1), 1-11 (2007).
53. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004).
54. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006).
55. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 27(8), 1227-1234 (2009).
56. Sequist LV, Bell DW, Lynch TJ et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 25(5), 587-595 (2007).
57. Costa DB, Kobayashi S, Tenen DG et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58(1), 95-103 (2007).
58. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).
59. Lee JS, Park K, Kim S-W et al. A randomized Phase III study of gefitinib (IRESSA™) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. Presented at: 13th World Conference on Lung Cancer. San Francisco, CA, USA, 31 July-4 August 2009.
60. Kobayashi K, Inoue A, Maemondo M et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a Phase III study (002) by North East Japan Gefitinib Study Group. Proc. Am. Soc. Clin. Oncol. (2009) (Abstract CRA 8016).
61. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010).
62. Hida T, Okamoto I, Kashii T et al. Randomized Phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG). J. Clin. Oncol. 26 (2008) (Abstract LBA8012).
63. Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN: a double-blind, randomized, Phase III study of maintenance erlotinib versus placebo following non-progression with first-line platinum-based chemotherapy in patients with advanced NSCLC. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May- 2 June 2009.
64. Miller V, O'Connor P, Soh C et al. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
65. Raben D, Helfrich B, Chan DC et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. 11(2 Pt 1), 795-805 (2005).
66. Butts CA, Bodkin D, Middleman EL et al. Randomized Phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J. Clin. Oncol. 25(36), 5777-5784 (2007).
67. Rosell R, Robinet G, Szczesna A et al. Randomized Phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19(2), 362-369 (2008).
68. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009).
69. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561-566 (2007).
70. Choi YL, Takeuchi K, Soda M et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 68(13), 4971-4976 (2008).
71. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27(26), 4247-4253 (2009).
72. Kwak EL, Camidge D, Clark J. Clinical activity observed in a Phase 1 dose escalation trial of an oral C-MET and ALK inhibitor, PF-02341066. J. Clin. Oncol. 27(15 Suppl.) (2009) (Abstract 3509).
73. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13(2), 139-147 (2008). (Pubitemid 351342577)
74. Papadimitrakopoulou V, Soria JC, Douillard JY et al. A Phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer failing prior platinum-based chemotherapy or chemotherapy and EGFR inhibitors. J. Thoracic Oncol. 2 (Suppl. 4), S359 (2007) (Abstract C1-04).
75. Milton DT, Riely GJ, Azzoli CG et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110(3), 599-605 (2007).
76. Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14(4), 399-411 (2009).
77. Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled Phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J. Clin. Oncol. 25(27), 4270-4277 (2007).
78. Natale RB, Bodkin D, Govindan R et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double blind, randomized Phase II trial. J. Clin. Oncol. 24, 7000 (2006) (Abstract).
79. Herbst R, Sun Y, Korfee S et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind Phase III trial (ZODIAC). Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
80. de Boer R, Arrieta O, Gottfried M et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized double-blind Phase III trial (ZEAL). Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
81. Ross HJ, Blumenschein GR Jr, Aisner J et al. Randomized Phase II multicenter trial of two schedules of lapatinib as first-or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin. Cancer Res. 16(6), 1938-1949 (2010).
82. Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J. Thorac. Oncol. 3(6 Suppl. 2), S131-S134 (2008).
83. Socinski MA, Novello S, Brahmer JR et al. Multicenter, Phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol. 26(4), 650-656 (2008).
84. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008).
85. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786-792 (2005). (Pubitemid 40271173)
86. Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J. Thorac. Oncol. 3(6 Suppl. 2), S146-S149 (2008).
87. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702-4711 (2008).
88. Spicer J, Calvert H, Vidal L et al. Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor in non-small cell lung cancer with mutated EGFR. Presented at: World Lung Cancer Congress. Seoul, South Korea, 2-6 September 2007 (Abstract D7-02).
89. Yang C, Shih J, Su W et al. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). Presented at: ASCO Annual Meeting 2010. Chicago, IL, USA, 4-8 June 2010 (Abstract 7521).
90. Induction erlotinib therapy in stage III A (N2) non-small cell lung cancer (NSCLC) http://clinicaltrials.gov/ct2/show/NCT00600587
91. Induction chemotherapy followed by CCRT according to EGFR mutation status in NSCLC III http://clinicaltrials.gov/ct2/show/NCT00620269
92. Randomized Phase III multicenter trial of RRM1 & ERCC1 directed customized chemotherapy versus standard of care for 1st line treatment of patients with advanced non-small-cell lung cancer http://clinicaltrials.gov/ct2/ show/NCT00499109